RK
RKDA.US Arcadia Biosciences Inc
- Market cap
- USD 1.15M
- P/E
- -
- P/B
- 0.81x
- ROE
- -493.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RKDA.US undervalued?
Graham numberThe Graham number of Arcadia Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arcadia Biosciences Inc fundamental analysis
No fundamental analysis for Arcadia Biosciences Inc yet.
Arcadia Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Da…
Full company profileArcadia Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arcadia Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.19M | 4.03M | 1.46M | 1.17M | 8.03M | 6.78M | 7.42M | 4.45M | 5.05M | 4.86M | 5.55M |
| Gross Profit | 2.29M | 3.74M | 803K | 284K | 2.84M | -1.93M | 1.32M | 2.28M | 2.08M | 1.76M | 2.52M |
| Operating Income | -18.6M | -14.3M | -16.9M | -19.4M | -12.8M | -35.5M | -14.0M | -6.10M | -3.65M | -10.00M | -2.82M |
| EBITDA | -18.0M | -14.7M | -13.3M | -28.7M | -5.44M | -27.7M | -14.7M | -5.73M | -6.85M | -2.30M | -11.9M |
| Net Income | -19.6M | -15.7M | -13.5M | -28.8M | -4.66M | -14.7M | -15.4M | -14.0M | -7.04M | -2.34M | -11.9M |
| EPS | -354 | -291 | -143 | -181 | -19 | -28 | -26 | -11 | -5.16 | -1.71 | -1.96 |
| Balance Sheet | |||||||||||
| Total Assets | 56.6M | 16.6M | 24.0M | 32.6M | 47.3M | 43.9M | 28.9M | 19.7M | 13.5M | 6.55M | 4.72M |
| Total Liabilities | 34.4M | 8.56M | 11.2M | 24.2M | 18.8M | 12.7M | 8.02M | 7.00M | 7.29M | 2.41M | 2.31M |
| Shareholders' Equity | 22.2M | 8.01M | 12.8M | 7.71M | 27.7M | 31.1M | 21.0M | 12.8M | 6.22M | 4.14M | 2.40M |
| Cash & Short-term Investments | 50.6M | 13.0M | 21.8M | 25.3M | 25.7M | 28.7M | 20.6M | 11.6M | 4.24M | 4.56M | 2.84M |
| Total Debt | 25.1M | - | - | 2.24M | 9.35M | 3.29M | 2.02M | 1.01M | 155K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.1M | -14.0M | -13.6M | -17.2M | -30.2M | -25.9M | -14.0M | -15.3M | -9.63M | -4.74M | -3.60M |
| Capital Expenditure | 231K | 79.0K | 250K | 1.48M | 2.34M | 1.01M | 72.0K | 5.00K | 16.0K | 0.00 | 0.00 |
| Free Cash Flow | -17.3M | -14.0M | -13.9M | -18.7M | -32.6M | -26.9M | -14.0M | -15.3M | -9.64M | -4.74M | -3.60M |
| Ratios | |||||||||||
| ROE | -88.4% | -196.2% | -105.2% | -373.8% | -16.8% | -47.1% | -73.1% | -108.9% | -113.1% | -56.5% | -493.6% |
| ROA | -34.7% | -94.8% | -56.1% | -88.4% | -9.8% | -33.4% | -53.2% | -71.0% | -52.1% | -35.7% | -251.5% |
| Net Profit Margin | -615.6% | -390.1% | -920.8% | -2,464.1% | -57.9% | -216.2% | -207.3% | -313.9% | -139.5% | -48.1% | -213.7% |
| Debt to Equity | 1.13x | - | - | 0.29x | 0.34x | 0.11x | 0.10x | 0.08x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arcadia Biosciences Inc dividends
Arcadia Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Mar 1, 2023.
Who owns Arcadia Biosciences Inc
- Insiders 15.87%
- Institutions 17.69%
- Public & others 66.44%
- Shares outstanding 6.07M
- Free float 2.17M
Top funds holding RKDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 12.4K | 0.24% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.72K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.63K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding RKDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 88.4K | 3.67% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 23.7K | 0.99% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 21.8K | 0.90% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 16.1K | 0.67% | -49.17% | Jun 2026 |
| XTX Topco Ltd | 15.5K | 0.64% | 0.00% | Jun 2026 |
| StoneX Group Inc | 13.7K | 0.57% | 0.00% | Jun 2026 |
| State Street Corp | 12.1K | 0.50% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 10.2K | 0.43% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.64K | 0.40% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 120.00 | 0.01% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 70.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 35.00 | 0.00% | -95.66% | Jun 2026 |
| Group One Trading, LLC | 18.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Southern Michigan Bank & Trust | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Genworth Financial Wealth Mgmt Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sabby Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Arcadia Biosciences Inc company profile
- Company name
- Arcadia Biosciences Inc
- Ticker
- RKDA.US
- Exchange
- USA Stocks
- Listed since
- May 15, 2015
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 8
- Fiscal year end
- December
- Address
- 5956 Sherry Lane, Dallas, TX, United States, 75225
- Phone
- 214 974 8921
- Website
- arcadiabio.com
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Arcadia Biosciences Inc management
1- Mr. Thomas J. Schaefer C.F.A.CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director · born 1976